Press Releases

Five-year survival data from pivotal Phase 3 Study 309/KEYNOTE-775 trial evaluating lenvatinib plus pembrolizumab in certain patients with advanced endometrial carcinoma Efficacy outcomes in...

Multiple endometrial carcinoma abstracts to be presented, including long-term follow-up data for lenvatinib plus pembrolizumab in advanced disease from Study 309/KEYNOTE-775 Final bone metastases...

Long-Term Follow-Up Data from LEAP-002 Offers Insights into Hepatocellular Carcinoma Treatment Pipeline Data in Endometrial Carcinoma Among Studies to be Presented NUTLEY, N.J., May 20, 2025...

In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone Late-breaking first interim analysis...

Late-breaking results from the Phase 3 LEAP-012 trial offer further insight into the treatment of patients with unresectable, non-metastatic hepatocellular carcinoma (HCC); data are selected for...

Eisai today announced a label update for LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in the United States to include clinical efficacy data for...

Eisai today announced results from a post-hoc analysis from the Phase 3 REFLECT trial, which looked at efficacy outcomes characterized by depth of response in patients with unresectable...

Biomarker Analyses from Pivotal Phase 3 CLEAR Trial in Patients with Advanced Renal Cell Carcinoma Will Be Featured in an Oral Presentation Additional Data From Eisai's Pipeline Provide Insights...

Data from the Pivotal Phase 3 CLEAR Trial and Phase 2 KEYNOTE-B61 Trial Provide Further Insight into the Role of Lenvatinib Plus Pembrolizumab as a First-Line Treatment Option for Patients with...

Longer-Term Efficacy and Safety Results from the Phase 3 LEAP-002 Trial Offer Additional Information About the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma Data on...